It was great to join the Convenzis team again for the patient flow event. As always, the team were incredibly accommodating and happy to help. The quality of attendees is always of a high standard and relevant to the patient flow and to us also. We continue to have great discussions and footfall around our stand with no need to try and encourage people to come and see us. Really positive event for us and we look forward to working with Convenzis in the future.
ADVANZ PHARMA
Correvio Pharma Corp, is a speciality pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide. Correvio develops, acquires and commercialises brands for the in-hospital, acute care market segment.
The Company’s portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of severe bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Also, Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications. Correvio’s pipeline of product candidates includes Trevyent®. A drug-device combination that is designed to deliver treprostinil, the world’s leading treatment for pulmonary arterial hypertension. Correvio is traded on the NASDAQ Capital Market (CORV)
